Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Graves Diseases - Overview
Graves Diseases - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Graves Diseases - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves Diseases - Companies Involved in Therapeutics Development
advanceCor GmbH
Apitope Intertiol NV
AV7 Ltd
Cytodyn Inc
GlaxoSmithKline Plc
Omeros Corp
Rodos BioTarget GmbH
Virtici LLC
Graves Diseases - Drug Profiles
ATXGD-59 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-170 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leronlimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein for Graves Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GPR174 for Immunology, Neurology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Graves Diseases and Graves Ophthalmopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTCG-90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Graves Diseases - Dormant Projects
Graves Diseases - Product Development Milestones
Featured News & Press Releases
Jun 20, 2019: Apitope announces publication of data in intertiol peer-reviewed jourl thyroid on Graves’ disease Therapy
Aug 14, 2018: Apitope Announces Publication of Graves’ Disease Data in Intertiol Peer-Reviewed Jourl, Endocrinology
Apr 16, 2018: Apitope Announces Positive Results with Novel Treatment for Graves Disease
Oct 26, 2016: Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves Disease
Jun 19, 2014: Apitope Progresses Graves’ Disease Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Graves Diseases, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Graves Diseases, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Graves Diseases - Pipeline by advanceCor GmbH, H1 2020
Graves Diseases - Pipeline by Apitope International NV, H1 2020
Graves Diseases - Pipeline by AV7 Ltd, H1 2020
Graves Diseases - Pipeline by Cytodyn Inc, H1 2020
Graves Diseases - Pipeline by GlaxoSmithKline Plc, H1 2020
Graves Diseases - Pipeline by Omeros Corp, H1 2020
Graves Diseases - Pipeline by Rodos BioTarget GmbH, H1 2020
Graves Diseases - Pipeline by Virtici LLC, H1 2020
Graves Diseases - Dormant Projects, H1 2020